BioGaia's 33% EBIT Margin Came With an IOU Against Q4

Q3 2026 delivered 23% growth and a 54% profit jump — but it borrowed orders from the fourth quarter, banked a tariff refund, and re-issued last quarter's promise that Asia Pacific is about to arrive

BIOG-B.ST · Earnings Call · 2026-10-22

The headline quarter, and what was tucked inside it

BioGaia's Q3 2026 is the kind of print a small-cap healthcare name dreams about. Net sales of SEK 400 million, “our growth, excluding currency effects, is 23% for the quarter... our EBIT margin is at 33%” — Theresa Agnew, CEO · 2026-10-22 versus 26% a year earlier, operating profit up 54% to SEK 132 million, EPS at SEK 1.09 from SEK 0.65. Both segments fired: pediatrics +21% and adult health +29% at constant currency, with the adult franchise now the faster horse for a second consecutive quarter. EMEA +38%, Americas +23%. Then management volunteered the asterisk. EMEA's 38% included customers moving orders out of Q4 and into Q3. Asked to size it, the CEO declined but was unambiguous about materiality and mix: “we won't quantify a specific number, but it is substantial, which is why we are talking about it, so that we give some direction around Q4, and it is mainly with the pediatrics business” — Theresa Agnew, CEO · 2026-10-22 That is unusually candid, and it is the single most important sentence on the call. Q3 was funded by Q4. That framing also explains the margin optics. Gross margin slipped to 73% from 74%, driven by a 2-point decline in pediatrics. Two analysts tried to pin the softness on the lumpy pulled-forward EMEA orders; the CFO resisted both times, insisting it was “more mix effects between both geographies and products” — Alexander Kotsinas, CFO · 2026-10-22 — the same geography-and-product-mix explanation he gave in Q2, when he described gross margin moves as “mainly due to normal or, well, variations between geography and products” — Alexander Kotsinas, CFO · 2026-07-17. Recurring explanation, recurring 1-point drift. Investors should start treating the gross line as a mix residual rather than a signal.

A tariff refund — and a market-wide theme

Buried in the CFO's remarks: SEK 3.2 million of U.S. refunds tied to the IEEPA tariff regime, which flattered the quarterly gross margin. On a SEK 292 million gross profit base that is roughly a point — small, but it is the difference between "gross margin down 1pp" and "down 2pp." More interesting is the confluence: the IEEPA refund is currently one of the loudest themes in the whole market's curated keyword set, sitting near the very top of the global league table, and it showed up in this reporting cycle from a footwear brand and a defense prime as well as a probiotic maker. This is the rare case where BioGaia is riding a genuinely broad wave rather than a company-specific one — and equally rare in that management mentioned it once and moved on. Last quarter's tariff refunds line was a novelty; this quarter it is a market-wide tailwind that will not repeat.

The second promise on Asia Pacific

The real tension is regional. APAC grew just 8% at constant currency, and pediatrics in APAC actually declined. Back in July the setup was supposed to be resolved already: “we do expect... that our China distributor will increase their orders in Q3 and then larger orders in Q4 as well” — Theresa Agnew, CEO · 2026-07-17 The third quarter came, and China orders did not deliver the step-up. Management's response is to promise it again, harder:

In terms of Q4, we do expect orders to pick up in the Asia-Pacific region. So we anticipate strong results for Asia-Pacific in Q4.
Theresa Agnew, CEO · 2026-10-22

Pressed on whether that meant growth against a very tough prior-year Q4 comp, the CEO doubled down: “we would expect in Q4 to have strong year-over-year growth, even from the quarter last year” — Theresa Agnew, CEO · 2026-10-22 That is now a two-quarter-old promise with one missed delivery behind it, and it sits against a candid admission that China's consumer economy is slowing. Note also what quietly vanished from the keyword set: last quarter's order variability language and explicit China-distributor colouring are gone, replaced by a generic Asia Pacific pledge. When a company stops quantifying a problem and starts asserting the outcome, the burden of proof shifts to the next print.

Marketing spend versus the 34% target

The third thread is the one that got the most airtime in Q&A. Reported OPEX grew only 2%, but that included a SEK 14 million FX gain on receivables. Strip it out and true operating cost growth was low-teens against 23% sales growth. One analyst framed it sharply: selling and marketing costs grew around 70% versus a 19% gross profit increase. The CEO's answer was a restatement of ambition rather than a plan: “Our long-term target is 34% for EBIT margin. We don't give specific guidance, but we anticipate getting to the long-term target over the next couple of years” — Theresa Agnew, CEO · 2026-10-22 Here the contrast with the prior call is stark. In July the CFO said “we're committed to try to keep our total OpEx basically flat for this year” — Alexander Kotsinas, CFO · 2026-07-17 That commitment is now visibly broken, and management has replaced it with a multi-year margin aspiration plus an assurance that marketing cost can be dialled back without hurting growth. Both things cannot be verified until the marketing lever is actually pulled. The bull case — that this spend is buying share in the direct market build-out across France, Germany and Austria, plus Holland & Barrett in the UK — is credible and shows up in the 38% EMEA number. The bear case is that EMEA's growth was part borrow, and the spend is the part that stays.

Where the genuine novelty sits

Not everything is arithmetic. The launch of BioGaia Colus, built on the proprietary BG-R59 strain and backed by two independent randomised trials, opens a colon health flank alongside the existing gut and oral franchises. It started in the UK with a selective global roll-out to follow, and it is genuinely company-unique — no other reporter in this cycle is talking about it, and it is not a category the market tape is pricing. That, plus a Capital Markets Day in London on 8 December, gives management a fresh venue to re-set the multi-year story. What the price tape would normally tell us is missing here — there is no usable price series for this name in the data — so the read has to come entirely from the fundamentals and the transcript. On that basis the quarter is real but pre-spent: a 33% EBIT margin propped by a pull-forward, a tariff refund and an FX gain, against a Q4 that now has to clear a hard Asia Pacific promise and a tougher EMEA comparison. Watch three things on the next print: whether APAC Q4 growth actually arrives, whether EMEA normalises rather than reverses, and whether lower margin mix keeps showing up as an explanation rather than a problem. BioGaia is growing; the question is how much of Q3 it already owned before it started.